Thoracoscopic talc pleurodesis for recurrent, symptomatic pleural effusion following cardiac operations

Surg Laparosc Endosc Percutan Tech. 2003 Oct;13(5):339-44. doi: 10.1097/00129689-200310000-00011.

Abstract

Seventeen patients who underwent a cardiac operation developed a recurrent, symptomatic pleural effusion ultimately requiring video-assisted thoracic surgery (VATS) and talc pleurodesis. These patients represented 0.4% of all patients undergoing a cardiac operation over the same time period. Compared with an age- and sex-matched control group of cardiac surgery patients, patients requiring VATS for recurrent pleural effusion were more obese with higher body mass index (31.9 +/- 1.2 versus 28.3 +/- 1.4 kg/M2, P = 0.03), were more likely to have undergone a complex cardiac operation (8/17 versus 1/17, P =.01) and were more frequently on anticoagulation and antiplatelet agents besides aspirin (8/17 versus 2/17, P =.02). Patients underwent 1.86 +/- 0.34 thoracenteses with drainage of 846 +/- 166 mL/thoracentesis prior to referral for VATS. On average, patients underwent VATS 4.83 +/- 1.49 months after their cardiac operation. There were 3 VATS-related complications (17.6%) and no deaths. VATS talc pleurodesis led to symptomatic and radiologic improvement in all patients with a mean follow-up of 8.2 +/- 1.5 months. VATS talc pleurodesis effectively and safely treats the unusual postcardiac surgery patient with refractory pleural effusion.

MeSH terms

  • Aged
  • Cardiac Surgical Procedures / adverse effects*
  • Female
  • Humans
  • Irritants / therapeutic use*
  • Male
  • Middle Aged
  • Pleural Effusion / etiology
  • Pleural Effusion / surgery*
  • Pleurodesis / methods*
  • Recurrence
  • Retrospective Studies
  • Talc / therapeutic use*
  • Thoracic Surgery, Video-Assisted / methods*
  • Treatment Outcome

Substances

  • Irritants
  • Talc